Bladder Cancer | Disease Landscape & Forecast | G7 | 2021
The 2016 and 2017 FDA approvals of multiple immune checkpoint inhibitors for advanced bladder cancer have greatly altered the treatment landscape for this disease. The FDA’s (2020) and EC’s (2021) approvals of Bavencio (Merck KGaA / Pfizer) as a maintenance treatment for first-line locally advanced or metastatic disease and the FDA’s approval of Keytruda (Merck & Co.) for non-muscle-invasive BCG-unresponsive disease highlight the expanded use of immune checkpoint inhibitors across lines of therapy. The approval of Padcev (Seagen / Astellas) will have a significant impact on the market, with label expansions across the G7 for use in combination with Keytruda for muscle-invasive and metastatic disease. Given the intense Phase II/III pipeline activity, we anticipate the approval of several new therapies for various populations by 2030.
QUESTIONS ANSWERED
- What are the sizes of the clinically and commercially relevant drug-treatable bladder cancer populations, and how will drug-treatment rates change over time?
- How is bladder cancer currently treated, and what are the key advantages and disadvantages of existing drugs? What is the expected market impact of recent approvals?
- Which of the emerging therapies are viewed as most promising, and what sales / uptake could they secure in the bladder cancer market?
- What are the drivers of and constraints in the bladder cancer market, and how will the market evolve over the ten-year forecast period?
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will feature continuous updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
